Peri-interventional coronary vasomotion

Area of Science:

• Cardiology
• Vascular Biology
• Pharmacology

Background:

• Percutaneous coronary intervention (PCI) can trigger ischemia-reperfusion injury due to compromised coronary vasomotor function.
• Severe coronary atherosclerosis impairs endothelial and autoregulatory vasodilation, exacerbating vasoconstriction post-PCI.

Purpose of the Study:

• To investigate the efficacy of intracoronary alpha-blockade in counteracting post-PCI vasoconstriction.
• To evaluate the impact of selective alpha(1)- and alpha(2)-blockade on coronary hemodynamics and left ventricular (LV) function.

Main Methods:

• Intracoronary administration of non-selective (phentolamine), selective alpha(1) (urapidil), and selective alpha(2) (yohimbine) blockade.
• Assessment of coronary vasoconstriction, coronary vascular resistance, coronary flow reserve, and LV function in patients undergoing PCI.

Main Results:

• Alpha(1)-blockade with urapidil dilated epicardial arteries, enhanced coronary flow reserve, and improved LV function.
• Non-selective alpha-blockade with phentolamine caused epicardial and microvascular dilation.
• Selective alpha(2)-blockade showed minimal vasodilator and functional effects; alpha-blockade attenuated the no-reflow phenomenon.

Conclusions:

• Intracoronary alpha(1)-blockade is a promising strategy to mitigate post-PCI vasoconstriction and improve outcomes.
• Alpha-blockade effectively addresses diffuse coronary vasoconstriction, including non-culprit lesions, and reduces the no-reflow phenomenon.